^
Association details:
| Biomarker: | FANCA deletion |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Excerpt:
Next-generation sequencing identified homozygous deletions, deleterious mutations, or both in DNA-repair genes--including BRCA1/2, ATM, Fanconi's anemia genes, and CHEK2--in 16 of 49 patients who could be evaluated (33%)...Patient 26, who had a somatic homozygous deletion of both BRCA1 and FANCA, had a response...
DOI:
10.1056/NEJMoa1506859
Trial ID:
